View Older Stories View More Recent Stories

Nov 9, 2017 06:45AM Merck Receives FDA Approval of PREVYMIS™ (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
Nov 7, 2017 04:00AM Merck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years
Nov 6, 2017 05:00PM Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
Nov 6, 2017 08:56AM Merck Announces Any and All Tender Offers
Nov 2, 2017 09:00AM Merck Publishes Annual Corporate Responsibility Report
Nov 1, 2017 09:00AM Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
Oct 27, 2017 04:18PM Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC
Oct 27, 2017 04:17PM Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Oct 27, 2017 06:45AM Merck Announces Third-Quarter 2017 Financial Results
Oct 23, 2017 08:30PM Corning to Showcase Latest in Pharmaceutical Glass Technologies at CPhI Worldwide in Frankfurt, Germany
Oct 23, 2017 06:59AM Merck (MRK) & AstraZeneca PLC (AZN) Report Second Regulatory Submission to Rapidly Advance LYNPARZA (olaparib) in Japan
Oct 23, 2017 06:55AM AstraZeneca and Merck Rapidly Advance LYNPARZA® (olaparib) in Japan With a Second Regulatory Submission
Oct 23, 2017 05:47AM Merck (MRK) Announces Data from Real-World Study Shows ZEPATIER (Elbasvir and Grazoprevir)
Oct 21, 2017 02:00PM Real-World Study Shows ZEPATIER® (Elbasvir and Grazoprevir) Resulted in High Rates of Sustained Virologic Response in Patients with Chronic Hepatitis C Infection Who Have Chronic Kidney Disease
Oct 18, 2017 07:01AM Merck (MRK) and AstraZeneca (AZN) Granted FDA Acceptance of Regulatory Submission for LYNPARZA (Olaparib)
Oct 18, 2017 06:55AM U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
Oct 18, 2017 06:47AM Merck (MRK) Says KEYTRUDA More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic NSCLC with High Levels of
Oct 18, 2017 06:45AM Merck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell
Oct 12, 2017 01:00PM Merck Makes $3 Million Charitable Donation to Support Swim Across America
Oct 12, 2017 06:55AM Merck Joins with the American Liver Foundation to Educate U.S. Veterans on Chronic Hepatitis C Virus (HCV) Infection
Oct 11, 2017 04:47PM Merck (MRK) Says it Won't Submit Applications for Regulatory Approval for Anacetrapib
Oct 11, 2017 04:45PM Merck Provides Update on Anacetrapib Development Program
Oct 10, 2017 08:04AM Merck (MRK) Announces Six-year Efficacy Data for GARDASIL 9 Presented at EUROGIN 2017 Congress
Oct 10, 2017 08:00AM Six-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Congress
Oct 4, 2017 08:05AM Merck (MRK) Reports 40 Data Presentations at ID Week 2017
Oct 4, 2017 08:00AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases With 40 Data Presentations at ID Week 2017
Oct 3, 2017 06:58AM Merck (MRK) to Present New Data on ZEPATIER for Treatment of Chronic HCV Infection at The Liver Meeting
Oct 3, 2017 06:55AM Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting® 2017
Sep 29, 2017 06:57AM Merck (MRK) to Discontinue MK-3682B and MK-3682C Development Programs for HCV
Sep 29, 2017 06:56AM Merck (MRK) Says New and Updated Data on KEYTRUDA to Be Presented at WCLC
Sep 29, 2017 06:55AM Merck Discontinues MK-3682B and MK-3682C Development Programs
Sep 29, 2017 06:55AM New and Updated Clinical Data on Merck’s KEYTRUDA® (pembrolizumab) to Be Presented at 18th World Conference on Lung Cancer
Sep 28, 2017 09:00AM Merck Animal Health Extends Commitment to Fighting Rabies in the World’s Most At-Risk Regions
Sep 27, 2017 06:45AM Merck to Hold Third-Quarter 2017 Sales and Earnings Conference Call on October 27
Sep 22, 2017 03:32PM Merck (MRK) Says FDA Approves KEYTRUDA for Recurrent Metastatic Gastric or GEJ Cancer Whose Tumors Express PD-L1
Sep 22, 2017 03:30PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (
Sep 21, 2017 06:23AM Merck KGaA, Pfizer (PFE) Report European Commission Approval for Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Sep 21, 2017 03:13AM European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Sep 19, 2017 07:00AM Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer
Sep 11, 2017 09:02AM Merck (MRK) Says Phase 3 Study of KEYTRUDA Compared to Standard of Care in Patients with Previously Treated HNSCC Didn't Meet Primary Endpoint
Sep 11, 2017 09:00AM Merck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcino
Sep 11, 2017 06:57AM Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance
Sep 11, 2017 05:48AM Incyte (INCY) Reports Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with Merck (MRK) KEYTRUDA (pembrolizumab)
Sep 10, 2017 08:45AM Merck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Pos
Sep 9, 2017 08:45AM Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melano
Sep 8, 2017 10:36AM Merck (MRK) Reports KEYTRUDA (pembrolizumab) plus Pemetrexed & Carboplatin (pem/carbo) Demonstrated Continued Benefit
Sep 8, 2017 10:33AM Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in P
Sep 8, 2017 08:04AM Merck (MRK) Says Updated Data for KEYTRUDA in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO
Sep 8, 2017 08:00AM Updated Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress
Sep 7, 2017 08:52AM Dr. Sam Bozzette Joins Premier Inc. to Lead Its Research Division
View More Recent Stories View Older Stories